Patents

Exclusive license secured to patents covering arterial chlamydial granuloma therapy

Published in Heart Disease Weekly, August 31st, 2003

ActivBiotics, Inc., announced that it has exclusively licensed a suite of patents (U.S. 5,424,187; U.S. 5,830,874; U.S. 6,043,225) from the University of Washington covering the diagnosis and treatment of arterial chlamydial granuloma.

Researchers at the University of Washington were the first to discover Chlamydia pneumoniae, the organism linked by researchers from around the globe to atherosclerotic plaques. The organism is theorized by many to cause or exacerbate chronic inflammatory diseases such as atherosclerosis. Rifalazil, ActivBiotics lead compound, is believed by the company to be the most potent antichlamydial compound in clinical testing, and if...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Heart Disease Weekly

Source: Heart Disease Weekly (2003-08-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry